title: [Bone alkaline phosphatase and N-MID osteocalcin in monitoring of osteoporosis treatment with recombinant human parathyroid hormone 1-34].
abstract: OBJECTIVE
  To evaluate the application of bone turnover markers bone alkaline phosphatase (BALP) and N-MID osteocalcin (N-MID) in monitoring of osteoporosis treatment with recombined parathyroid hormone 1-34 (rhPTH1-34).
  
  
  METHODS
  The bone mineral density (BMD) of the lumbar spine L2-L4 and the proximal femur were examined by dual energy X-ray absorptiometry (DXA) before and 6 and 12 months after rhPTH 1-34 treatment. Meanwhile, serum levels of BALP and N-MID were detected by electro-chemiluminescence assay.
  
  
  RESULTS
  Six months after rhPTH 1-34 treatment, the BMD of proximal femur remained unchanged, and the BMD of the lumbar L2-L4 spine increased from 0.753 g/cm(2) to 0.781 g/cm(2) (P<0.05); while serum levels of N-MID increased from 15.46 ng/ml to 27.07 ng/ml(P<0.01), BALP from 14.05 μg/ml to 24.31 μg/ml(P<0.01). Twelve months after drug administration, no significant changes were observed in BMD of proximal femur, and the BMD of the lumbar spine L2-L4 increased from 0.753 g/cm(2) to 0.807 g/cm(2)(P<0.01) while serum levels of N-MID and BALP increased from 15.46 ng/ml and 14.05μg/ml to 49.38 ng/ml and 33.99 μg/ml, respectively (both P<0.01).
  
  
  CONCLUSIONS
  Serum levels of BALP and N-MID are more sensitive than BMD. Combination of two methods may provide better indicators for monitoring of osteoporosis treatment.
authors.affiliation: Department of Basic, Zhejiang University School of Medicine, Hangzhou 310058, China.
authors.forename: Xiu-Mei
authors.initials: XM
authors.lastname: Weng
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Pan
mesh_terms: D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood*; D015519:Bone Density; D005260:Female; D005269:Femur / Q000000981:diagnostic imaging; D006801:Humans; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*; D010024:Osteoporosis / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D011859:Radiography; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D010281:Parathyroid Hormone; D011994:Recombinant Proteins; D015675:Osteocalcin; D000469:Alkaline Phosphatase